News

Company   ImmuPharma PLC
TIDM         IMM
Headline     Update on Phase IIa Clinical Trial
Released   13:08 19-Oct-2010
Number     6358U13

FOR IMMEDIATE RELEASE

London, 19 October 2010

Update on Phase IIa Clinical Trial with
Cancer Compound IPP-204106

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company"or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce that at today's analyst briefing, Dr Robert Zimmer, Chief Scientific Officer, will give the following update on ImmuPharma's exciting Cancer programme IPP-204106, the summary of which is detailed below:

Dose escalating open label study commenced in patients with at least one treatment failure according to standard regulatory guidelines;

The study was designed to show safety and tolerability and assess the maximum tolerated dose;

Patients are dosed with an initial dose of 40 mg/sq.m. or 1 mg/kg and if stabilisation or improvement occurs, then patients continue treatment for an additional 4 sessions;

6 patients have been dosed so far, suffering from either breast cancer, lung cancer and bladder cancer and all with metastasis

No serious drug-related adverse events have so far been reported; and

2 patients have already been rated as having stabilised disease.

ImmuPharma plans to file a US IND in the next few months and to commence a Phase IIb programme the first half of 2011 in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer and pancreatic cancer, which will be confirmed by additional preclinical data.

For further information please contact:

ImmuPharma PLC

Dr Robert Zimmer, President & Chief Scientific Officer     + 33 389 32 76 50
Dimitri Dimitriou, Chief Executive Officer                         +44 20 7152 4080
Richard Warr, Chairman                                                +44 20 7152 4080

Buchanan Communications +44 20 7466 5000

Lisa Baderoon, Mark Court, Jessica Fontaine

Panmure Gordon & Co., NOMAD & Broker 44 20 7459 3600

Andrew Burnett
Rakesh Sharma

Execution Noble & Co., Joint Broker +44 20 7456 9191

James Bromhead
Richard Crawley


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	News Company ImmuPharma PLC TIDM IMM Headline Update on Phase IIa Clinical Trial Released 13:08 19-Oct-2010 Number 6358U13 FOR IMMEDIATE RELEASE London, 19 October 2010 Update on Phase IIa Clinical Trial with Cancer Compound IPP-204106 ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company"or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce that at today's analyst briefing, Dr Robert Zimmer, Chief Scientific Officer, will give the following update on ImmuPharma's exciting Cancer programme IPP-204106, the summary of which is detailed below: Dose escalating open label study commenced in patients with at least one treatment failure according to standard regulatory guidelines; The study was designed to show safety and tolerability and assess the maximum tolerated dose; Patients are dosed with an initial dose of 40 mg/sq.m. or 1 mg/kg and if stabilisation or improvement occurs, then patients continue treatment for an additional 4 sessions; 6 patients have been dosed so far, suffering from either breast cancer, lung cancer and bladder cancer and all with metastasis No serious drug-related adverse events have so far been reported; and 2 patients have already been rated as having stabilised disease. ImmuPharma plans to file a US IND in the next few months and to commence a Phase IIb programme the first half of 2011 in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer and pancreatic cancer, which will be confirmed by additional preclinical data. For further information please contact: ImmuPharma PLC Dr Robert Zimmer, President & Chief Scientific Officer + 33 389 32 76 50 Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080 Richard Warr, Chairman +44 20 7152 4080 Buchanan Communications +44 20 7466 5000 Lisa Baderoon, Mark Court, Jessica Fontaine Panmure Gordon & Co., NOMAD & Broker 44 20 7459 3600 Andrew Burnett Rakesh Sharma Execution Noble & Co., Joint Broker +44 20 7456 9191 James Bromhead Richard Crawley ©2010 London Stock Exchange plc. All rights reserved